| Name | Title | Contact Details |
|---|
Cole Harbour Place is a Dartmouth, NS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Western Berks Ambulance Association is a Reading, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Windsor Health Plan, Inc. is a Medicare Advantage plan with a Medicare contract, and a Medicare-approved Part D Sponsor, whose core purpose is to improve health and well being, peace of mind and financial security for our members when navigating health care coverage options. A partnership between Windsor Health Plan and Sterling Life Insurance Company since 2011, the organization can now provide more resources, member support and plan options for Medicare Advantage beneficiaries and is a leader in the provision of health care to Medicare- and Medicaid-eligible members seeking to enhance their quality of life. Windsor Health Plan manages government sponsored health plans and provides specialty managed care services to insurance providers and to health care providers. Windsor Health Plan is a division of Windsor Health Group, with corporate offices in Atlanta and operational offices in Nashville, Tenn. and Bellingham, Wash., as well as regional offices throughout the United States.
Electrical Geodesics is a Eugene, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.